Researchers at Stanford University are hoping that brain-machine interfaces, or neural prosthetics, could become a clinical reality to help cure Parkinson’s disease. The scientific interest in connecting the brain with machines and devices isn’t new. It began in the 1970s with Jacques Vidal’s Brain Computer Interface project. The project…
Following the recent merger of the National Parkinson Foundation and the Parkinson’s Disease Foundation, the newly created Parkinson’s Foundation has launched a new brand and website as part of its mission to help those living with Parkinson’s disease (PD). The new website is www.parkinson.org. John Kozyak, chair of the…
Two Purdue University professors are using the global phenomenon known as the Nintendo Wii gaming system to help Parkinson’s disease patients improve their movement, speech, and quality of life. The professors in the College of Health and Human Sciences, Jessica Huber and Jeff Haddad, are particularly interested in studying how…
Two Parkinson’s disease specialists have been named the co-leaders of a New York University movement disorders institute. Drs. Andrew Feigin and Steven J. Frucht are co-executive directors of the Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders at the university’s Langone Health Center. “Having two movement disorders…
Rock Steady Boxing is a nonprofit organization that seeks to improve the quality of life of Parkinson’s disease (PD) patients by providing a venue for exercise through noncontact boxing, a concept designed to boost coordination, motor skills, balance, and speech. Researchers have found that Parkinson’s patients who exercise…
The first patient has been treated in a clinical trial evaluating Titan Pharmaceuticals’ ropinirole implants, designed to treat the signs and symptoms of Parkinson’s disease. The Phase 1/2 study (NCT03250117) is taking place at three clinical sites in the U.S. that specialize in Parkinson’s research. Researchers…
AC Immune is receiving additional funding from the Michael J. Fox Foundation for Parkinson’s Research to continue developing positron emission tomography (PET) tracers for alpha-synuclein, a protein linked to Parkinson’s disease. The idea behind the project is to use alpha-synuclein as a biomarker of Parkinson’s. The PET tracers will help…
Herantis Pharma has started the first clinical trial of cerebral dopamine neurotrophic factor (CDNF) as a potential treatment for Parkinson’s disease. The first patient in the Phase 1/2 clinical trial has enrolled at the Karolinska University Hospital in Stockholm. The study will also involve another hospital in Sweden…
Researchers at Australia’s RMIT University have developed the first tool capable of diagnosing early signs of Parkinson’s disease even before symptoms are visible — offering new prospects for more effective treatments. Their study, Distinguishing Different Stages of Parkinson’s Disease Using Composite Index of Speed and Pen-Pressure of Sketching a Spiral,” appeared…
An ongoing Phase 1b trial of VY-AADC01, a gene therapy for the treatment of advanced Parkinson’s disease (PD), is showing positive results, including improvement of motor function and activities of daily living, durable clinical effects, and good tolerability. The announcement was made by Voyager Therapeutics, the gene therapy company specialized…
Get regular updates to your inbox.